HIV-1 peptide-HLA complex (HIV pHLA)

HIV-derived conserved peptide/HLA complexes are molecular structures formed when fragments of HIV proteins, particularly from highly conserved regions like Gag or Pol, are processed and presented on the surface of infected cells by Human Leukocyte Antigen (HLA) molecules (PubMed: 25133735). These complexes serve as the primary signal for the cellular immune system, specifically CD8+ cytotoxic T lymphocytes, to identify and eliminate virally infected cells (NIH: NIAID HIV Research). Because HIV has a high mutation rate, targeting conserved peptides—sequences that remain relatively stable across different viral strains—is a critical strategy for developing broadly effective immunotherapies (Nature Communications: 10.1038/s41467-018-04075-1). Therapeutic approaches targeting these complexes include T-cell receptor (TCR) engineered T-cells and bispecific molecules like ImmTAVs (e.g., GSK3903371), which bridge the peptide-HLA complex with T-cells to trigger a potent immune response (Immunocore: ImmTAV Technology). By focusing on these stable targets, researchers aim to overcome the challenge of viral diversity and the presence of the latent HIV reservoir. However, challenges such as HIV-mediated downregulation of HLA molecules by the Nef protein and potential cross-reactivity with human self-peptides must be carefully managed (Journal of Virology: 10.1128/JVI.01216-16).

Other names

HIV-1 peptide-MHC complexHIV-1 pMHCConserved HIV epitope-HLA complexHIV-1 antigen-HLA complexHIV-derived peptide-HLA class I complex

Therapeutic agents such as TCR-based bispecifics or engineered T-cells bind specifically to the HIV peptide-HLA complex on the surface of infected cells, facilitating the recruitment and activation of cytotoxic T-cells to induce apoptosis of the target cell.